Stock market today: Wall Street ticks higher ahead of the Fed’s decision on interest rates
U.S. stocks are ticking higher ahead of the Federal Reserve’s announcement coming later in the afternoon about what it will ...
McKesson upgraded at Baird on Core Ventures deal after Q2 beat
Baird upgraded McKesson (NYSE:MCK) to outperform from neutral on Thursday, citing the updates the medical distributor gave ...
Fintel on MSN8h
Baird Upgrades McKesson (MCK)
Fintel reports that on November 7, 2024, Baird upgraded their outlook for McKesson (NYSE:MCK) from Neutral to Outperform. ...
McKesson's Fiscal Q2 EPS Tops Forecast
McKesson's earnings for its fiscal 2025 second quarter exceeded expectations, despite special charges that cut into net ...
McKesson: Strong Q2 Performance and Raised FY 2025 Guidance Justify Buy Rating
McKesson (MCK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Allen Lutz ...
Jury in Baltimore opioid trial to begin deliberating ‘biggest and most important case in the city’s history’
Jurors are slated to begin deliberations Friday morning after lawyers for the city and companies, McKesson and ...
McKesson’s Strong Q2 Performance Leads to Upward EPS Revision, But Hold Rating Due to Segment Concerns and Uncertain Long-Term Growth
Steve Baxter, an analyst from Wells Fargo, maintained the Hold rating on McKesson (MCK – Research Report). The associated price target ...
McKesson Corp (MCK) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...
McKesson Corp (MCK) reports a 21% revenue increase and raises fiscal 2025 EPS guidance amid strategic expansions and ...
MarketWatch9h
McKesson Shares Jump After FY25 Outlook Boost, Strong 2Q Sales
Shares of McKesson climbed after the drug distributor raised its fiscal-year guidance and reported strong sales growth during its fiscal second quarter. The stock was up 11%, at $610.99, in midday ...
These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings
McKesson MCK reported better-than-expected second-quarter financial results on Wednesday. McKesson reported quarterly earnings of $7.07 per share which beat the analyst consensus estimate of $6.88 per ...
What you need to know in Baltimore’s opioid case before it heads to jurors
Fletcher-Hill sends the case to the jury for consideration. Baltimore alleges that the companies, McKesson and AmerisourceBergen, flooded the city with hundreds of millions of addictive pain pills ...